PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Bempedoic acid - Lipid modification
PAD Profile : Bempedoic acid - Lipid modification
Keywords :
Primary hypercholesterolaemia, mixed dyslipidaemia, lipid-lowering, lipid lowering, raised cholesterol, high cholesterol
Brand Names Include :
Nilemdo
Traffic Light Status
Status 1 of 1.
Status :
Green
Important
Formulations :
- Tablets
Important Information :
Only as add-on therapy for patients already on ezetimibe.
Use the combination product (bempedoic acid with ezetimibe) in new patients.
Specialist team initiation and supply of at least 3 months before transfer of prescribing to primary care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Simvastatin with fenofibrate
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid with ezetimibe
- Inclisiran
- Icosapent
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
04 December 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a GREEN traffic light status for bempedoic Acid with ezetimibe in line with NICE guidance (TA694).
Please follow the guidance in the SPC and the National Lipid Management pathway for advice on initial and onward monitoring requirements.
Note: Anaemia is a common side-effect of bempedoic acid. For patients where a reduction in haemoglobin (Hb) may be of concern, consider a full blood count (FBC) at 3 months and annually thereafter.
Associated BNF Codes
02. Cardiovascular System
02.12.00. Lipid-regulating drugs